<DOC>
	<DOCNO>NCT00788073</DOCNO>
	<brief_summary>The study objective explore efficacy , safety tolerability STX209 treatment irritability subject FSX . We hypothesize STX209 improve irritability typical problem behavior associate fragile X syndrome . We also hypothesize STX209 safe well tolerate .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Study STX209 Subjects With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Male female subject 12 40 year age eventually expand 6 year age Molecular documentation fragile X mutation . Clinical Global Impression Severity ( CGIS ) rating problem behavior moderate high screen Visit 1 An Aberrant Behavior Checklist ( ABCC ) Irritability Subscale score &gt; 12 least 3 item Irritability Subscale rat least moderate . Current treatment three psychoactive medication , include antiepileptic . Current pharmacological treatment regimen stable least 4 week . Subjects history seizure disorder currently receive treatment antiepileptic . Subjects condition , include alcohol drug abuse , might interfere conduct study , confound interpretation study result , endanger wellbeing . This include , limited impairment renal function , evidence history malignancy significant hematological , endocrine , cardiovascular , respiratory , hepatic , gastrointestinal disease . Subjects plan initiate change pharmacologic nonpharmacologic intervention course study . Subjects currently receive treatment racemic baclofen . Subjects currently treat vigabatrin tiagabine . Subjects take another investigational drug currently within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>fragile X syndrome</keyword>
	<keyword>irritability</keyword>
	<keyword>behavior problem</keyword>
</DOC>